News
Q32 Bio
QTTB · NASDAQ
$8.62+$0.83 (+10.65%)TodayMarket closed ·
Prev close $7.79
Latest news
- Press releasePRNewswire
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
- Press releasePRNewswire
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
- Press releasePRNewswire
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
- Press releasePRNewswire
Q32 Bio to Participate in Upcoming September Investor Conferences
- Press releasePRNewswire
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- NewsAkanksha Bakshi
Why Is Q32 Bio Stock Falling Wednesday?
- Press releasePRNewswire
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
- NewsAvi Kapoor
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releasePRNewswire
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- NewsAvi Kapoor
Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
- NewsAvi Kapoor
US Stocks Mixed; Dow Gains Over 100 Points
- NewsVandana Singh
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why
- NewsRishabh Mishra
Stock Market Today: Dow Jones, Nasdaq 100, S&P 500 Futures Slips as US and Iran Exchange Strikes— Saratoga, Exxon Mobil, Levi's Strauss In Focus (UPDATED)
- News
Market-Moving News for July 13th
- Press releasePRNewswire
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
- NewsAvi Kapoor
FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday
- Press releasePRNewswire
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
- NewsLekha Gupta
Why Is Q32 Bio Stock Gaining Friday?
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releasePRNewswire
Q32 Bio Announces $55 Million Private Placement Financing
- News
Earnings Scheduled For May 5, 2026
- Press releasePRNewswire
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
- News
Q32 Bio Q4 Adj. EPS $3.65 Beats $(0.98) Estimate, Sales $53.737M
- Press releasePRNewswire
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
- Press releasePRNewswire
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Press releasePRNewswire
Q32 Bio Announces $10.5 Million Registered Direct Offering
- NewsAvi Kapoor
Crude Oil Gains Over 1%; ISM Manufacturing PMI Falls In November
- NewsAvi Kapoor
Dow Dips 200 Points; Q32 Bio Shares Jump
- NewsVandana Singh
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
- News
Market-Moving News for December 1st
- News
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
- Press releasePRNewswire
Q32 Bio Sells Complement Inhibitor ADX-097
- Press releasePRNewswire
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releasePRNewswire
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
- Press releasePRNewswire
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.